CryoCor's Scientific Advisory Board consists of leading physicians and researchers in the field of cardiology and cardiac electrophysiology and is active in assisting the Company's development of its products and clinical trials.
About CryoCor
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com
Forward-Looking Statements
The statements in this press release that are not descriptions of
historical facts are forward-looking statements that are subject to risks
and uncertainties. These include statements related to the potential
advantages of CryoCor's cryoablation system and CryoCor's opportunities in
the field of atrial fibrillation ablation, all of which are prospective.
Such statements are only predictions and reflect CryoCor's expectations and
assumptions as of the date of this press release based on currently
available operating, financial, and competitive information. The actual
events or results may differ materially from
'/>"/>
| SOURCE CryoCor, Inc. Copyright©2008 PR Newswire. All rights reserved |